Mar. 12 at 8:40 PM
$KRMD
Earnings
KORU Medical Systems reported strong financial results for Q4 and full year 2024, with significant growth across all business segments.
Q4 net revenues reached
$8.8 million, up 23% year-over-year, while full-year revenues hit
$33.6 million, an 18% increase.
The company's Core business saw Q4 revenues of
$8.2 million (+19% YoY), while Novel Therapies revenue grew 122% to
$0.7 million.
Gross margin improved to 62.9% in Q4 and 63.4% for the full year.
The company ended 2024 with
$9.6 million in cash, achieving positive cash flow of
$0.8 million in Q4.
For 2025, KORU Medical projects net revenues between
$38.0-
$39.0 million (13-16% growth), with gross margins of 61-63%.
The company expects to be operational cash flow positive for full year 2025.
Additionally, the Novel Therapies business will be renamed to Pharma Services and Clinical Trials (PST) starting Q1 2025.
